SCHEMBL8937346

SCHEMBL8937346

CCCOc1ccc(/C(=C/C(=O)O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.54
LMNA P02545 2/20 0.54
ALDH1A1 P00352 2/20 0.54
NFKB1 P19838 1/20 0.54
CASP3 P42574 1/20 0.54
RAB9A P51151 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
L3MBTL1 Q9Y468 3/20 0.50
PLK1 P53350 1/20 0.50
TP53 P04637 4/20 0.47
TSHR P16473 1/20 0.47
MAPT P10636 3/20 0.46
THRB P10828 1/20 0.46
MAOB P27338 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937347 1.00 NPC1 (0.54) NPC1LMNAALDH1A1NFKB1CASP3
SCHEMBL8937343 1.00 NPC1 (0.54) NPC1LMNAALDH1A1NFKB1CASP3
SCHEMBL8937615 0.87 MAPT (0.60) NPC1LMNAALDH1A1NFKB1CASP3
SCHEMBL8937565 0.87 MAPT (0.60) NPC1LMNAALDH1A1NFKB1CASP3
SCHEMBL8937571 0.87 MAPT (0.60) NPC1LMNAALDH1A1NFKB1CASP3
SCHEMBL8937229 0.87 L3MBTL1 (0.46) NPC1LMNAALDH1A1NFKB1CASP3
SCHEMBL8937235 0.87 L3MBTL1 (0.46) NPC1LMNAALDH1A1NFKB1CASP3
SCHEMBL8937232 0.87 L3MBTL1 (0.46) NPC1LMNAALDH1A1NFKB1CASP3
SCHEMBL8937282 0.83 NR1H4 (0.47) NPC1LMNAALDH1A1RAB9ASMN1; SMN2
SCHEMBL8937288 0.83 NR1H4 (0.47) NPC1LMNAALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed